Triskel Biopharmaceuticals AG, headquartered in Basel, Switzerland is specialised in the development of late stage and clearly differentiated biotechnology drugs, with a focus on the very sizeable speciality hospital paediatric market.
The corporate and development group and its founder members and management are all experienced pharmaceutical and healthcare professionals, each with more than 20 years of experience in their respective fields of expertise.
The lead compound in development by Triskel Bio is TB 101, an innate recombinant-human enzyme, identified by the company as serving an underserved therapeutic area of high unmet medical need, namely in preventing and reducing long-term chronic respiratory morbidity (CRM) in the population of prematurely born neonatal patients. Other clinical indications for TB 101 are also subsequently envisaged.
TRISKEL BIO is interested to share more detailed information (extensive business plan available) with potential investors in this project.